Showing results (331-340 of 361) with videos related to
Sort By:
Pageof 37
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2025
Targeting BCL11B in CAR-engineered lymphoid progenitors drives NK-like cell development with prolonged anti-leukemic activityFranziska Baatz, Arnab Ghosh, Jessica Herbst, et al.British Journal of Haematology|February 4, 2020
Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 childrenTheodor Uden, Alice Bertaina, Jonas Abrahamsson, et al.Academic Pediatrics|December 22, 2021
Fellow Entrustment for the Common Pediatric Subspecialty Entrustable Professional Activities Across SubspecialtiesSarah Pitts, Alan Schwartz, Carol L Carraccio, et al.The New England Journal of Medicine|December 10, 2021
Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-ThalassemiaFranco Locatelli, Alexis A Thompson, Janet L Kwiatkowski, et al.Inflammatory Bowel Diseases|June 4, 2018
Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression ProfilesRaguraj Chandradevan, Tatyana Hofmekler, Kajari Mondal, et al.Journal of Medical Education and Curricular Development|August 27, 2020
Agreement of Program Directors With Clinical Competency Committees for Fellow EntrustmentRichard Mink, Bruce E Herman, Carol Carraccio, et al.Blood Advances|January 6, 2023
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from GermanyPeter Bader, Claudia Rossig, Martin Hutter, et al.Cancer Research|June 5, 2013
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHDArnab Ghosh, Amanda M Holland, Yildirim Dogan, et al.Blood|January 12, 2026
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemiaJanet L Kwiatkowski, Alexis A Thompson, Jennifer Schneiderman, et al.Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.Pageof 37